Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 14/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.46 |
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5282684 | 0.88 | ESR2 (0.54) | DGAT1ESR2ESR1 | |
| SCHEMBL14137121 | 0.85 | DGAT1 (0.63) | DGAT1 | |
| SCHEMBL14062343 | 0.85 | DGAT1 (0.63) | DGAT1 | |
| SCHEMBL14061891 | 0.85 | DGAT1 (0.48) | DGAT1ESR2ESR1 | |
| SCHEMBL14137124 | 0.83 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL15690662 | 0.83 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL14062083 | 0.81 | DGAT1 (0.62) | DGAT1ESR2ESR1 | |
| SCHEMBL14062151 | 0.81 | DGAT1 (0.62) | DGAT1ESR2ESR1 | |
| SCHEMBL14061848 | 0.78 | DGAT1 (0.51) | DGAT1ESR2ESR1 | |
| SCHEMBL14137087 | 0.78 | DGAT1 (0.51) | DGAT1ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624174-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885ESR2 211/4885ESR1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.